Powder: -20°C for 3 years | In solvent: -80°C for 1 year
RWJ-67657 (JNJ 3026582) 是一种可口服的选择性p38α和p38β抑制剂,IC50分别为 1 和 11 μM。它是心脏保护剂,具有抗炎和抗肿瘤活性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 283 | 现货 | ||
2 mg | ¥ 395 | 现货 | ||
5 mg | ¥ 659 | 现货 | ||
10 mg | ¥ 996 | 现货 | ||
25 mg | ¥ 2,320 | 现货 | ||
50 mg | ¥ 3,720 | 现货 | ||
100 mg | ¥ 5,380 | 现货 | ||
500 mg | ¥ 11,200 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 728 | 现货 |
产品描述 | RWJ-67657 (JNJ 3026582) is an orally active and selective p38α and p38β MAPK inhibitor (IC50s: 1 and 11 μM, respectively). RWJ-67657 shows no activity at p38γ and p38δ and shows a cardioprotective effect. |
靶点活性 | p38β:11 μM, p38α:1 μM |
体外活性 | RWJ-67657 suppresses the release of TNF-α by lipopolysaccharide (LPS)-treated human peripheral blood mononuclear cells (IC50: 3 nM) and the release of TNF-α from peripheral blood mononuclear cells treated with the superantigen staphylococcal enterotoxin B (IC50: 13 nM). RWJ67657 (10 μM; 24 hours) reduces colony formation in MCF-7 cells [2][3]. |
体内活性 | RWJ-67657 inhibits TNF-alpha production in lipopolysaccharide-injected mice (87% inhibition at 50 mg/kg) and in rats (91% inhibition at 25 mg/kg) after oral administration. RWJ-67657 (50 mg/kg; p.o.; once per day for 7 consecutive days) shows an effective anti-inflammatory effect. EPC transplantation plus RWJ-67657 administration synergistically promotes angiogenesis and neurogenesis after diabetic stroke by both improving the functioning of endothelial progenitor cells and reducing inflammation [2][4]. |
别名 | JNJ 3026582 |
分子量 | 425.5 |
分子式 | C27H24FN3O |
CAS No. | 215303-72-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (293.77 mM), ultrasonic and warming and heat to 60°C
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3502 mL | 11.7509 mL | 23.5018 mL | 58.7544 mL |
5 mM | 0.47 mL | 2.3502 mL | 4.7004 mL | 11.7509 mL | |
10 mM | 0.235 mL | 1.1751 mL | 2.3502 mL | 5.8754 mL | |
20 mM | 0.1175 mL | 0.5875 mL | 1.1751 mL | 2.9377 mL | |
50 mM | 0.047 mL | 0.235 mL | 0.47 mL | 1.1751 mL | |
100 mM | 0.0235 mL | 0.1175 mL | 0.235 mL | 0.5875 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
RWJ-67657 215303-72-3 MAPK p38 MAPK RWJ67657 RWJ 67657 Inhibitor JNJ3026582 JNJ 3026582 anti-tumor JNJ-3026582 p38α protective. Anti-inflammatory MCF-7 inhibit inflammation cardio p38β inhibitor